Physician profile
Tamara Sealy
NPI 1225477094
$3,636.61
in general payments reported to CMS, 2019-2025
28 companies · $18.66 in 2025
The $18.66 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,262 · 2020: $369 · 2021: $332 · 2022: $273 · 2023: $392 · 2024: $990 · 2025: $18.66.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,400.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,399.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $868.25 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $462.86 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals Lp | $368.34 | 2019-2024 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $283.29 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $252.92 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $219.10 | 2019-2024 | Jardiance, Synjardy |
| Pfizer INC. | $156.13 | 2019-2024 | |
| Janssen Pharmaceuticals, INC | $115.52 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $112.35 | 2019-2022 | |
| Amgen INC. | $106.91 | 2023-2024 | Otezla, Repatha, Prolia |
| Abbvie INC. | $101.55 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $77.01 | 2019-2024 | Xifaxan |
| Merck Sharp & Dohme LLC | $66.87 | 2019 | |
| Novartis Pharmaceuticals Corporation | $65.19 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $43.41 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $43.30 | 2024 | |
| Abbott Laboratories | $38.85 | 2021-2024 | Freestyle Libre 3 |
| Exact Sciences Corporation | $37.04 | 2024 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $36.72 | 2022 | |
| Lundbeck LLC | $27.56 | 2024 | Rexulti |
| Ironwood Pharmaceuticals, INC | $27.03 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $22.57 | 2024 | Voquezna |
| Biogen, INC. | $22.20 | 2021 | |
| Esperion Therapeutics, INC. | $20.25 | 2021 | |
| Dexcom, INC. | $19.61 | 2022 | |
| Sanofi Pasteur INC. | $16.31 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $14.02 | 2021 | |
| Genentech USA, INC. | $11.45 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Sealy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.